127 related articles for article (PubMed ID: 10972538)
21. Inhibitory effects of amlodipine and fluvastatin on the deposition of advanced glycation end products in aortic wall of cholesterol and fructose-fed rabbits.
Akira K; Amano M; Okajima F; Hashimoto T; Oikawa S
Biol Pharm Bull; 2006 Jan; 29(1):75-81. PubMed ID: 16394514
[TBL] [Abstract][Full Text] [Related]
22. Effect of 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors (statins) on tissue paraoxonase 1 and plasma platelet activating factor acetylhydrolase activities.
Bełtowski J; Wójcicka G; Jamroz A
J Cardiovasc Pharmacol; 2004 Jan; 43(1):121-7. PubMed ID: 14668577
[TBL] [Abstract][Full Text] [Related]
23. Fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, suppresses very low-density lipoprotein secretion in puromycin aminonucleoside-nephrotic rats.
Moritomo Y; Hirano T; Ebara T; Kurokawa M; Naito H; Furukawa S; Nagano S
Nephron; 1994; 67(2):218-25. PubMed ID: 8072613
[TBL] [Abstract][Full Text] [Related]
24. Fibromuscular cap composition is important for the stability of established atherosclerotic plaques in mature WHHL rabbits treated with statins.
Shiomi M; Ito T; Hirouchi Y; Enomoto M
Atherosclerosis; 2001 Jul; 157(1):75-84. PubMed ID: 11427206
[TBL] [Abstract][Full Text] [Related]
25. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits.
Fukumoto Y; Libby P; Rabkin E; Hill CC; Enomoto M; Hirouchi Y; Shiomi M; Aikawa M
Circulation; 2001 Feb; 103(7):993-9. PubMed ID: 11181475
[TBL] [Abstract][Full Text] [Related]
26. Peroxynitrite-mediated oxidative modification of low-density lipoprotein by aqueous extracts of cigarette smoke and the preventive effect of fluvastatin.
Yamaguchi Y; Matsuno S; Kagota S; Haginaka J; Kunitomo M
Atherosclerosis; 2004 Feb; 172(2):259-65. PubMed ID: 15019535
[TBL] [Abstract][Full Text] [Related]
27. Direct effects of statins on the vascular wall.
Corsini A; Pazzucconi F; Arnaboldi L; Pfister P; Fumagalli R; Paoletti R; Sirtori CR
J Cardiovasc Pharmacol; 1998 May; 31(5):773-8. PubMed ID: 9593078
[TBL] [Abstract][Full Text] [Related]
28. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine.
Holdaas H; Hartmann A; Stenstrøm J; Dahl KJ; Borge M; Pfister P
Am J Cardiol; 1995 Jul; 76(2):102A-106A. PubMed ID: 7604781
[TBL] [Abstract][Full Text] [Related]
29. Pravastatin sodium, a competitive inhibitor of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase, decreases the cholesterol content of newly secreted very-low-density lipoprotein in Watanabe heritable hyperlipidemic rabbits.
Shiomi M; Ito T
Metabolism; 1994 May; 43(5):559-64. PubMed ID: 8177044
[TBL] [Abstract][Full Text] [Related]
30. Antioxidative effects of fluvastatin and its metabolites against DNA damage in streptozotocin-treated mice.
Imaeda A; Kaneko T; Aoki T; Kondo Y; Nakamura N; Nagase H; Yoshikawa T
Food Chem Toxicol; 2002 Oct; 40(10):1415-22. PubMed ID: 12387303
[TBL] [Abstract][Full Text] [Related]
31. Effects of pravastatin on cholesterol metabolism of cholesterol-fed heterozygous WHHL rabbits.
Harsch M; Gebhardt A; Reymann A; Lang G; Schliack M; Löser R; Braesen JH; Niendorf A
Br J Pharmacol; 1998 May; 124(2):277-82. PubMed ID: 9641543
[TBL] [Abstract][Full Text] [Related]
32. Protective effect of fluvastatin, an HMG-CoA reductase inhibitor, on the formation of 8-oxo-2'-deoxyguanosine in the nuclear DNA of hamster pancreas after a single administration of N-nitrosobis(2-oxopropyl)amine.
Kaneko T; Tahara S; Takabayashi F
Biol Pharm Bull; 2003 Sep; 26(9):1245-8. PubMed ID: 12951466
[TBL] [Abstract][Full Text] [Related]
33. Fluvastatin suppresses atherosclerotic progression, mediated through its inhibitory effect on endothelial dysfunction, lipid peroxidation, and macrophage deposition.
Bandoh T; Mitani H; Niihashi M; Kusumi Y; Kimura M; Ishikawa J; Totsuka T; Sakurai I; Hayashi S
J Cardiovasc Pharmacol; 2000 Jan; 35(1):136-44. PubMed ID: 10630744
[TBL] [Abstract][Full Text] [Related]
34. Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease.
Bevilacqua M; Bettica P; Milani M; Vago T; Rogolino A; Righini V; Santoli E; Norbiato G
Am J Cardiol; 1997 Jan; 79(1):84-7. PubMed ID: 9024745
[TBL] [Abstract][Full Text] [Related]
35. Fluvastatin reduces endothelin secretion of cultured human umbilical vein endothelial cells.
Mueck AO; Seeger H; Lippert TH
Eur J Clin Pharmacol; 1999 Nov; 55(9):625-6. PubMed ID: 10638389
[TBL] [Abstract][Full Text] [Related]
36. Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro.
Suzumura K; Yasuhara M; Tanaka K; Suzuki T
Biochem Pharmacol; 1999 Mar; 57(6):697-703. PubMed ID: 10037456
[TBL] [Abstract][Full Text] [Related]
37. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Corsini A; Raiteri M; Soma MR; Bernini F; Fumagalli R; Paoletti R
Am J Cardiol; 1995 Jul; 76(2):21A-28A. PubMed ID: 7604791
[TBL] [Abstract][Full Text] [Related]
38. Fluvastatin and fluvastatin extended release: a clinical and safety profile.
Asberg A; Holdaas H
Expert Rev Cardiovasc Ther; 2004 Sep; 2(5):641-52. PubMed ID: 15350166
[TBL] [Abstract][Full Text] [Related]
39. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits.
Rikitake Y; Kawashima S; Takeshita S; Yamashita T; Azumi H; Yasuhara M; Nishi H; Inoue N; Yokoyama M
Atherosclerosis; 2001 Jan; 154(1):87-96. PubMed ID: 11137086
[TBL] [Abstract][Full Text] [Related]
40. Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia.
Haak E; Abletshauser C; Weber S; Goedicke C; Martin N; Hermanns N; Lackner K; Kusterer K; Usadel KH; Haak T
Atherosclerosis; 2001 Apr; 155(2):395-401. PubMed ID: 11254910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
